ArticleJournal of medical biochemistry2025
The significance of serum sST2 and cfDNA in children with severe pneumonia complicated by myocardial damage.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The paper aimed to explore the significance of serum soluble ST2 (sST2) and circulating cell-free DNA (cfDNA) in predicting cardiac functions in children with severe pneumonia complicated by myocardial damage. Methods: This case series study evaluated the serum sST2 and cfDNA levels of 60 children with severe pneumonia complicated by myocardial damage, assessing clinical data, biomarker levels, and cardiac function. Results: We analyzed data from a cohort of 60 patients with a mean age of 4.47±1.88 years and a male: female ratio of 28:32. At baseline, patients had elevated levels of serum biomarkers, including sST2 and cfDNA, which were associated with cardiac function parameters and clinical outcomes. After 6 months, patients showed significant correlations between sST2, cfDNA, and cardiac function parameters, including left ventricular end-diastolic diameter (LVEDd), left ventricular end-systolic diameter (LVESd), and E/A ratio. Multivariate analysis revealed that higher levels of sST2 and cfDNA were associated with increased LVEDd, LVESd, and E/A ratio, as well as a lower likelihood of improvement and a higher likelihood of 6-month readmission. Conclusions: These findings suggest that sST2 and cfDNA may be useful biomarkers for predicting cardiac function and outcomes in this patient population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.